Should All Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease Receive an SGLT2 Inhibitor?

Arden R Barry (Pro), Bradley R Mitchelmore (Con)

Abstract


-

Full Text:

PDF HTML


DOI: http://dx.doi.org/10.4212/cjhp.v71i4.2831

ISSN 1920-2903 (Online)
Copyright © 2019 Canadian Society of Hospital Pharmacists